君实生物上周公布的2024年业绩快报显示,报告期内在营收同比增长29.67%的同时,亏损额收窄至12.82亿元,为近三年最低水平,君实生物将营收上涨归因于旗下药品的销售增长。 近年来,君实生物也在优化资源配置,聚焦于更有潜力的管线,随之而来便是“大砍”研发投入。截至2024年前三季度,君实生物研发投入为8.74亿元,而在2023年同期,这一数字为12.71亿元。 特瑞普利单抗去年国内销售额增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.